Antibiotic peptide derived from ribosomal protein L1 of
The present invention relates to a new antibiotic peptide and a usage thereof, which are derived from ribosomal protein L1, RPL1 of Helicobacter pylori . Specifically, the antibiotic peptide comprising the amino acid sequence of SEQ. ID. NO:1 derived from ribosomal protein L1, RPL1 of Helicobacter pylori is substituted with a Phenylalanine, which is situated at the first and the eighth position from the antibiotic peptide, or in addition an Asparagine, which is situated at the thirteenth position of the antibiotic peptide, is substituted with lysine, wherein the produced peptides have maintained more decreased cytotoxicity when comparing to the existing antibiotic peptides and can be used as a safe antibiotics by showing more antibacterial activity.
1. An antibiotic peptide comprising the amino acid sequence of SEQ ID NO: 1, wherein Phenylalanine, which is located at the first and the eighth position of the antibiotic peptide, is substituted with alanine and cytotoxicity is decreased.
2. The antibiotic peptide according to claim 1 , wherein the antibiotic peptide consists of the amino acid sequence of SEQ ID NO: 2.
3. An antibiotic peptide comprising the amino acid sequence of SEQ ID NO: 2, wherein an Asparagine, which is located at the thirteenth position of the antibiotic peptide, is substituted with a positively charged amino acid.
4. The antibiotic peptide according to claim 3 , wherein the antibiotic peptide comprises the amino acid sequence of SEQ ID NO: 3.
5. The antibiotic peptide according to claim 3 , wherein the positively charged amino acid is selected from the group consisting of lysine, arginine, and histidine.
6. A method for the prevention or treatment of a pathogenic bacterial disease, containing the step of administering pharmaceutically effective dose of the antibiotic peptide of claim 1 to a subject.
7. A method for the prevention or treatment of a pathogenic bacterial disease, containing the step of administering pharmaceutically effective dose of the antibiotic peptide of claim 3 to a subject.